Show simple item record

dc.contributor.authorHardwick, Lauraen
dc.contributor.authorDavies, Johnen
dc.contributor.authorPhilpott, Annaen
dc.date.accessioned2017-01-27T16:31:40Z
dc.date.available2017-01-27T16:31:40Z
dc.date.issued2016-12-02en
dc.identifier.issn0006-291X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/262099
dc.description.abstractMyoD is a master regulator of myogenesis with a potent ability to redirect the cell fate of even terminally differentiated cells. Hence, enhancing the activity of MyoD is an important step to maximising its potential utility for $\textit{in vitro}$ disease modelling and cell replacement therapies. We have previously shown that the reprogramming activity of several neurogenic bHLH proteins can be substantially enhanced by inhibiting their multi-site phosphorylation by proline-directed kinases. Here we have used Xenopus embryos as an $\textit{in vivo}$ developmental and reprogramming system to investigate the multi-site phospho-regulation of MyoD during muscle differentiation. We show that, in addition to modification of a previously well-characterised site, Serine 200, MyoD is phosphorylated on multiple additional serine/threonine sites during primary myogenesis. Through mutational analysis, we derive an optimally active phospho-mutant form of MyoD that has a dramatically enhanced ability to drive myogenic reprogramming $\textit{in vivo}$. Mechanistically, this is achieved through increased protein stability and enhanced chromatin association. Therefore, multi-site phospho-regulation of class II bHLH proteins is conserved across cell lineages and germ layers, and manipulation of phosphorylation of these key regulators may have further potential for enhancing mammalian cell reprogramming.
dc.description.sponsorshipThis work was supported by UK Medical Research Council (MRC) Research Grants MR/L021129/1 and MR/K01329/1, and core support from Wellcome Trust and MRC Cambridge Stem Cell Institute. LH was supported by an MRC Doctoral Training Award.
dc.languageengen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectMyoDen
dc.subjectmyogenesisen
dc.subjectphosphorylationen
dc.subjectbHLHen
dc.subject$\textit{Xenopus}$en
dc.subjectreprogrammingen
dc.titleMyoD phosphorylation on multiple C terminal sites regulates myogenic conversion activityen
dc.typeArticle
prism.endingPage103
prism.issueIdentifier1-2en
prism.publicationDate2016en
prism.publicationNameBiochemical and Biophysical Research Communicationsen
prism.startingPage97
prism.volume481en
dc.identifier.doi10.17863/CAM.7348
dcterms.dateAccepted2016-11-03en
rioxxterms.versionofrecord10.1016/j.bbrc.2016.11.009en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-12-02en
dc.contributor.orcidPhilpott, Anna [0000-0003-3789-2463]
dc.identifier.eissn1090-2104
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (MR/L021129/1)
pubs.funder-project-idMRC (MC_PC_12009)
cam.issuedOnline2016-11-04en
cam.orpheus.successThu Jan 30 12:53:51 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International